Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): October 10, 2008
 
Adeona Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
(State or other jurisdiction of
incorporation)
01-12584
(Commission
File Number)
13-3808303
(IRS Employer
Identification Number)
 
3930 Varsity Drive
Ann Arbor, MI 48108
(Address of principal executive offices) (Zip Code)
 
(734) 332-7800
(Registrant's telephone number, including area code)

Pipex Pharmaceuticals, Inc.
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
 
 
 o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
 
 
 
 
 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
 
Effective October 10, 2008, the Registrant amended its certificate of incorporation to change its corporate name to Adeona Pharmaceuticals, Inc. The Registrant’s previous corporate name was Pipex Pharmaceuticals, Inc.
 
Item 9.01   Financial Statements and Exhibits.

(d)  
Exhibits.

       Exhibit 3.1 Amendment to Certificate of Incorporation

       Exhibit 99.1  Press Release
       
SIGNATURE

 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  ADEONA PHARMACEUTICALS, INC.
   
Dated: October 16, 2008 By:  /s/ Nicholas Stergis
  Nicholas Stergis
  Chief Executive Officer